Genitourinary Cancer
News
Adding abiraterone improves suppression of intraprostate androgens
Key clinical point: Adding abiraterone to standard hormone therapy before prostatectomy suppresses androgens within the tumor tissue more...
News
Hypofractionation, vessel-sparing RT techniques for prostate cancer yield good QOL
Key clinical point: Men had good preservation of quality of life 3 years after hypofractionated radiation therapy and 5 years after vessel-sparing...
News
Trials close in on optimal ADT duration in high-risk prostate cancer
Key clinical point: Men who undergo radiation therapy for high-risk prostate cancer are less likely to have a recurrence and to die if they also...
News
Specific pattern of male baldness linked to aggressive prostate cancer
Key clinical point: If the association between this specific pattern of male baldness and aggressive prostate cancer is confirmed, this feature...
Original Report
Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel
News
Benefit from adjuvant RT for men with lymph node invasive prostate cancer varies with tumor characteristics
Key clinical point: Men with intermediate to high grade prostate cancer with one to two positive nodes, and all men with three to four positive...
News
FDA approves enzalutamide for chemo-naive metastatic prostate cancer
News
Androgen deprivation should be continued indefinitely in men with metastatic castration-resistant prostate cancer
News
Blood marker may signal enzalutamide, abiraterone resistance
Key clinical point: Detection of AR-V7 in the peripheral blood appears to be a marker of resistance to both enzalutamide and abiraterone treatment...
Original Report
Effects of exercise on disablement process model outcomes in prostate cancer patients undergoing androgen deprivation therapy
Conference Coverage
PSA density predicts progression of low-risk prostate cancer during active surveillance
Key clinical point: At 5 years after diagnosis of low-risk prostate cancer, most men who undergo active surveillance do not require treatment....